Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025

Core Viewpoint - Corbus Pharmaceuticals is hosting a KOL event to discuss dose optimization data from its Phase 1/2 clinical trial of CRB-701, targeting advanced solid tumors with high Nectin-4 expression [1][3]. Group 1: Event Details - The KOL event will take place on October 19, 2025, at the Berlin Germany Marriott, starting at 10 AM CEST [2]. - The event will include insights from leading experts in head and neck squamous cell carcinoma (HNSCC) and a live Q&A session [2]. Group 2: Clinical Trial Information - The ongoing clinical trial (NCT06265727) is evaluating the safety, pharmacokinetics, and efficacy of CRB-701 in patients with advanced solid tumors, primarily focusing on HNSCC and cervical cancer [3]. - Data from over 100 participants will be presented, highlighting the trial's significance in the oncology field [1]. Group 3: About CRB-701 - CRB-701 is a next-generation antibody drug conjugate (ADC) that targets Nectin-4, utilizing a cleavable linker and a drug antibody ratio of 2, with monomethyl auristatin E as the payload [7][8]. - Nectin-4 is recognized as a clinically validated tumor-associated antigen in urothelial cancer [8]. Group 4: Company Overview - Corbus Pharmaceuticals is a clinical stage oncology and obesity company focused on innovative scientific approaches to treat serious illnesses [9]. - The company's pipeline includes CRB-701, CRB-601 (an anti-integrin monoclonal antibody), and CRB-913 (a CB1 receptor inverse agonist for obesity) [9].